Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Item 8.01. Other Events

On March14, 2017, Axsome Therapeutics,Inc. (the Company)
updated its presentation slide deck in preparation for a
presentation by Herriot Tabuteau, M.D., Chief Executive Officer
of the Company, at the 29th Annual ROTH Conference (the
Conference) on March14, 2017. Dr.Tabuteau will be
presenting at the Conference to provide an overview of the
Companys business and late-stage clinical product candidates,
AXS-05 and AXS-02. Attached as Exhibit99.1 to this Current Report
on Form8-K is a copy of the presentation slide deck to be used in
connection with this presentation.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session up +0.05 at 5.25 with 36,487 shares trading hands.